Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

OBJECTIVES:

Primary

• Determine the maximum tolerated dose (MTD) of paclitaxel albumin-stabilized nanoparticle formulation given once weekly for 3 weeks when administered with carboplatin given once every 4 weeks.
• Determine the MTD of paclitaxel albumin-stabilized nanoparticle formulation given once every 3 weeks when administered with carboplatin given once every 3 weeks.
• Determine the MTD of paclitaxel albumin-stabilized nanoparticle formulation given in weeks 1 and 2 when administered with carboplatin given once every 3 weeks.
• Evaluate sequence-dependent effects on toxicity and pharmacokinetics in the combination of paclitaxel albumin-stabilized nanoparticle formulation and carboplatin.

Secondary

• Explore the antitumor activity of paclitaxel albumin-stabilized nanoparticle formulation given once weekly or once every 3 weeks.

OUTLINE: Patients are assigned to 1 of 3 treatment arms.

• Arm I: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
• Arm II: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
• Arm III: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients in arms I and II undergo blood sample collection periodically for pharmacokinetic studies.

After completion of study treatment, patients are followed at 30 days.

DISEASE CHARACTERISTICS:

Inclusion criteria

• Histologically or cytologically confirmed solid tumor

• Advanced or metastatic disease
• Measurable or evaluable disease
• Must meet 1 of the following criteria:

• Failed a standard therapy
• Not a candidate for standard therapy
• Have a disease for which there is no defined standard therapy

Exclusion criteria

• Symptomatic brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria

• ECOG performance status 0-2
• Life expectancy ≥ 8 weeks
• Absolute neutrophil count > 1,500/mm^3
• Platelet count > 100,000/mm^3
• Hemoglobin > 8.0 g/dL
• Total bilirubin normal
• Serum creatinine normal OR creatinine clearance ≥ 60 mL/min
• AST and ALT ≤ 2.5 x upper limit of normal
• Negative pregnancy test

Exclusion criteria

• Pregnant or lactating
• Prior anaphylactic reaction or severe allergic reaction to paclitaxel and/or docetaxel
• Active infection that requires treatment with antibiotics for > 4 weeks
• Uncontrolled congestive heart failure
• Symptomatic coronary artery disease or heart block
• Myocardial infarction within the past 3 months
• Peripheral neuropathy ≥ grade 2 from any cause

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy, radiotherapy, or any other therapy for malignancy within the past 3 weeks
• No concurrent filgrastim, pegfilgrastim, or sargramostim during the first course of therapy